drugset / Trial / NCT03159845

Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies

NCT03159845

Phase 2 Completed 20 enrolled Azienda Ospedaliero, Universitaria Pisana
RandomizedParallel-groupOpen-labelSupportive care

Summary

Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft. Patients of the Control group take only standard antimicrobial prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. Laboratory tests are performed on peripheral blood samples.

Timeline

Start
2014-01-01
Primary completion
2019-09-10
Completion
2019-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Zinc Sulfate Unknown 600 mg
Background Acyclovir Small molecule 400 mg
Background Fluconazole Small molecule 200 mg
Background Levofloxacin Small molecule 500 mg Oral